Humacyte (NASDAQ:HUMA) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $12.00 price target on the stock.

Several other equities analysts also recently issued reports on the stock. TD Cowen reaffirmed a “buy” rating and set a $10.00 price objective on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.00 price objective on shares of Humacyte in a research note on Friday, September 20th. Piper Sandler set a $6.00 price objective on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. BTIG Research restated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Finally, Benchmark reiterated a “buy” rating and set a $15.00 price target on shares of Humacyte in a report on Thursday, October 10th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and a consensus price target of $11.00.

Humacyte Stock Performance

HUMA opened at $5.34 on Wednesday. The firm’s 50-day moving average price is $5.45 and its 200-day moving average price is $6.18. The company has a market cap of $637.33 million, a P/E ratio of -3.99 and a beta of 1.47. Humacyte has a 52-week low of $2.35 and a 52-week high of $9.97. The company has a quick ratio of 5.41, a current ratio of 1.10 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). As a group, equities analysts anticipate that Humacyte will post -1.18 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Brady W. Dougan sold 252,676 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Humacyte news, CEO Laura E. Niklason sold 277,090 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $6.47, for a total transaction of $1,792,772.30. Following the completion of the transaction, the chief executive officer now owns 4,029,374 shares in the company, valued at $26,070,049.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the transaction, the director now owns 4,306,464 shares of the company’s stock, valued at approximately $28,896,373.44. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,084,153 shares of company stock valued at $6,869,996 in the last ninety days. Company insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. nVerses Capital LLC acquired a new position in shares of Humacyte during the 2nd quarter worth about $28,000. Concurrent Investment Advisors LLC purchased a new stake in Humacyte during the third quarter worth approximately $75,000. Principal Financial Group Inc. purchased a new position in Humacyte in the second quarter valued at approximately $83,000. FORA Capital LLC purchased a new position in Humacyte in the third quarter valued at approximately $96,000. Finally, Profund Advisors LLC acquired a new stake in Humacyte during the second quarter worth approximately $97,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.